YK11 is a synthetic, steroidal selective androgen receptor modulator (SARM) that acts as a gene-selective partial agonist of the androgen receptor (AR). Unlike traditional androgens, YK11 does not induce the N/C interaction, which is essential for full AR transactivation. T
his unique mechanism allows YK11 to exhibit potent anabolic activity in vitro, particularly in C2C12 myoblasts, where it demonstrates greater potency than dihydrotestosterone (DHT). Research indicates that YK11 enhances myogenic differentiation through follistatin expression and upregulates osteoblastic proliferation and differentiation in MC3T3-E1 cells, suggesting its potential in promoting bone health and muscle growth.
Additionally, YK11 has been investigated for its role in mitigating sepsis-induced muscle wasting, highlighting its diverse therapeutic potential.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | YK-11 |
|---|---|
| IUPAC Name | methyl (2E)-2-[(8R, 9S, 10R, 13S, 14S, 17S)-2'-methoxy-2', 13-dimethyl-3-oxospiro[1, 2, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16-dodecahydrocyclopenta[a]phenanthrene-17, 5'-1, 3-dioxolane]-4'-ylidene]acetate |
| CAS | 1370003-76-1 |
| Molecular Weight | 430.5 |
| Molecular Formula | C25H34O6 |
| SMILES | C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]24/C(=C\C(=O)OC)/OC(O4)(C)OC)CCC5=CC(=O)CC[C@H]35 |